NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology - With scalable, advanced resource and technology capabilities, Tergus presents pharma companies with exceptional CRO services for all their drug discovery and development requirements - TergusPharma.com / Frost.com
Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology

 

NewswireToday - /newswire/ - Santa Clara, CA, United States, 2021/03/08 - With scalable, advanced resource and technology capabilities, Tergus presents pharma companies with exceptional CRO services for all their drug discovery and development requirements - TergusPharma.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the North American contract research organization (CRO) market in dermatology, Frost & Sullivan recognizes TergusPharma (Tergus) with the 2020 North America Customer Value Leadership Award. It has continually built on technical, professional, and structural capabilities to deliver a functional service provider-like model that addresses specialty pharma’s needs in topical drug discovery and development programs. Its customer-centric, flexible, and tailored services deliver a real partner-level engagement, regardless of project size.

“Starting with high-quality R&D development services at the pre-clinical stage, Tergus steadily extended its capabilities to early skin biology services and clinical supplies manufacturing to deliver end-to-end development continuity. It is a market leader not only in R&D but also in manufacturing, making it an unmatched CRO within dermatological drug development,” said Surbhi Gupta, Industry Analyst at Frost & Sullivan. “The company has established itself as a strategic partner with flexible development capabilities, growing both organically as well as through acquisitions.”

Customer satisfaction and service flexibility have underpinned Tergus’ growth and investment strategies. In June 2019, Tergus announced its partnership with Great Point Partners to raise capital, and a month later, purchased a 100,000 square foot facility near its headquarters. Tergus is currently redesigning the space, building on existing clinical supplies manufacturing capabilities to establish the largest dermatology-related integrated R&D and production center in the United States. Within the next three to five years, Tergus expects to become the leading contract development and manufacturing organization in dermatology across the world.

The company works with customers across business verticals such as generics and novel drugs, driven mainly by large pharma, specialty pharma, and biotech startups. Its product and service diversification support strong growth regardless of changes in the industry; for instance, its investments in digital tools and new workflows have enabled it to respond to COVID-19’s potential consequences swiftly. Furthermore, it uses predictive analytics to ensure international supply procurement proactively for the clinical supplies needed, safeguarding participant’s well-being while adhering to clinical trial timelines.

“Tergus reports having at least 35% repeat customers, an impressive feat in a niche market. It also has a broad customer and project base, resulting in stable, continued year-over-year growth,” noted Norma Vela-Roch, Best Practices Research Analyst at Frost & Sullivan. “Its customer-focused innovations and strategic partnerships enable it to meet all current and future needs of its customers and continue to grow at an accelerated rate.”

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company’s unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For six decades, Frost & Sullivan (frost.com) has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

About TergusPharma
Tergus Pharma (terguspharma.com) is an end-to-end service provider for topical pharmaceutical research, drug development, testing, and manufacturing, and has been an industry leader for several years with a new 100,000 sq. ft. state-of-the-art facility in Durham, North Carolina. Focused exclusively on topical/skin liquids and semi-solids as well as other non-skin semi-solids/liquids for vaginal, rectal and otic/ophthalmic routes of administration, Tergus has a long and stellar reputation for delivering quality results to clients, from formulation through commercial manufacturing, earning the company the tagline,“Think Topicals, Think Tergus.” Tergus scientifically helps its clients achieve the right balance between speed and quality.

Tergus Contact:
Susan WingenF
P: 919-549-9702 - E: swingen[.]terguspharma.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Kristen Moore - Frost.com 
210-477-8469 kristen.moore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Global Natural History Study of Fibrodysplasia Ossificans Progressiva Shows Debilitating Impact of the Disease Over An Individual’s Lifetime
BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus
DSM Completes Acquisition of Prodap
Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  Luxury Executive Wellness





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)